NRX Pharmaceuticals, Inc.

Good afternoon, everyone, and welcome to the NRX Pharmaceuticals Incorporated second quarter of 2024 results conference call. Currently, all participants are in a listen-only mode. As a reminder, this conference call is being recorded. I will now turn the call over to Matthew Duffy, the company's chief business officer. Please go ahead.

Thank you, Franzi, and welcome, everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal security rules. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise forward-looking statements. Information presented on this call is contained in the press release issued today and in the company's Form 10-Q, which may be accessed from the investor's page of the NRX Pharmaceuticals website. Joining me today are Dr. Jonathan Javitt, our founder, chairman, and chief scientist, Stephen Willard, our chief executive officer, and Richard Narita, Chief Financial Officer and Treasurer. Stephen and Jonathan will provide a summary of our company's progress. Rich will review the company's financial results, and then Jonathan will review upcoming milestones before making closing comments. Following the prepared remarks, we will address investor questions.

I'll now turn the call over to Jonathan. Thank you, Matt.